Read More Pharma Industry News MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator. bySrinathOctober 18, 2025